Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Revista De Igiena, Bacteriologie, Virusologie, Parazitologie, Epidemiologie, Pneumoftiziologie. Bacteriologia, Virusologia, Parazitologia, Epidemiologia|July 1, 1980
["Minor" salmonelloses on the offensive; clinico-epidemiological aspects of Salmonella agona infections]T Hurmuzache, V Luca, E Râpeanu, et al.
Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi|January 16, 2015
[Investigations of the left ventricular dynamics in stable-angina pectoris (AP)]C I Negoiţă, C Marcu, S Barna, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 19, 2024
Bullous pemphigoid burden of disease, management and unmet therapeutic needsV P Werth, D F Murrell, P Joly, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 26, 2016
Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL-4Rα, in Atopic Dermatitis Patients and Normal VolunteersP Kovalenko, A T DiCioccio, J D Davis, et al.
The British Journal of Dermatology|September 30, 2019
Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trialsN Katoh, Y Kataoka, H Saeki, et al.
The British Journal of Dermatology|June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitisA Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|February 8, 2019
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitisG Yosipovitch, M Reaney, V Mastey, et al.
The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
Pageof 2